Skip to main content

Table 3 Summary of findings for the main comparison. Myoinositol supplementation compared to placebo for gestational diabetes mellitus and health outcomes

From: Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis

Summary of findings
Myoinositol compared to Placebo for gestational diabetes prevention
Patient or population: overweight and obese Pregnant women at increased risk of gestational diabetes
Setting: trials were carried from 1980s to 2021 in countries from Italy, Iran
Intervention: Myoinositol
Comparison: Placebo
Outcomes Anticipated absolute effectsa [95% CI] Relative effect [95% CI] No of participants [studies] Quality of the evidence [GRADE]
Risk with Placebo Risk with Myoinositol
Gestational diabetes rate [GDM Rate] 282 per 1000 112 per 1000 [66 to 141] OR 0.32 [0.21 to 0.48] 690 [4 RCTs] Ο MODERATE
FG-OGTT The mean of FG in the control groups was 84.7 The mean of FG in the intervention groups was 2.64 lower [4.12 to 1.17 lower]   690 [4 RCTs] Ο MODERATE
1 h-OGTT The mean of 1 hour-OGTT in the control groups was 142.3 The mean of 1 hour-OGTT in the intervention groups was 7.47 lower [12.24 to 2.31 lower]   690 [4 RCTs] ΟΟ LOW
2 h-OGTT The mean of 2 h-OGTT in the control groups was 121.1 The mean of 2 h-OGTT in the intervention groups was 10.51 lower [16.88 to 4.14 lower]   690 [4 RCTs] ΟΟ LOW
Gestational hypertension 27 per 1000 100 per 1000 [4 to 15] OR 0.26 [0.13 to 0.56] 690 [4 RCTs] Ο MODERATE
Preterm delivery 31 per 1000 88 per 1000 [4 to 25] OR 0.33 [0.14 to 0.81] 467 [3 RCTs] ΟΟ LOW
Cesarean section rate [CS rate] 424 per 1000 487 per 1000 [225 to 475] OR 0.77 [0.53 to 1.12] 467 [3 RCTs] ΟΟ LOW
Macrosomia 35 per 1000 50 per 1000 [10 to 69] OR 0.74 [0.28 to 1.95] 467 [3 RCTs] ΟΟ LOW
Neonatal hypoglycemia 0 per 1000 10 per 1000 [0] OR 0.34 [0.04 to 3.32] 411 [2 RCTs] ΟΟΟ VERY LOW
NICU admission 13 per 1000 46 per 1000 [1 to 17] OR 0.36 [0.10 to 1.32] 467 [3 RCTs] ΟΟ LOW
Shoulder dystocia 4 per 1000 8 per 1000 [0 to 21] OR 0.64 [0.08 to 5.25] 467 [3 RCTs] ΟΟΟ VERY LOW
  1. GRADE Working Group grades of evidence
  2. High quality: We are very confident that the true effect lies close to that of the estimate of the effect
  3. Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
  4. Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
  5. Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
  6. CI confidence interval, OR odds ratio, OGTT oral glucose tolerance test NICU neonatal intensive care unit admission
  7. aThe risk in the intervention group [and its 95% confidence interval] is based on the assumed risk in the comparison group and the relative effect of the intervention [and its 95% CI]